Zileuton CAS 111406-87-2

Asthma is a common chronic disease with a prevalence of about 10% in developed countries, and its morbidity and disability rate are increasing globally. As an important mediator of airway allergic inflammation, the successful study of leukotriene antagonists is a major breakthrough in asthma treatment in recent years.

Zileuton is a novel selective 5-lipoxygenase inhibitor that antagonizes leukotriene synthesis by inhibiting lipoxygenase. Leukotrienes are highly active inflammatory substances synthesized from tetraenoic acid via the lipoxygenase pathway, and play an important role in the pathogenesis of asthma. Zileuton mechanism of action is to effectively control the development of asthmatic inflammation by inhibiting the synthesis of leukotrienes. As a new class of anti-asthmatic drugs, zileuton has certain tracheal protection, tracheal expansion and anti-inflammatory effects. In the United States, the drug has been officially included in the National Asthma Education and Prevention Program in the United States due to its positive efficacy and small side effects, as a long-term treatment for asthma control (the currently included varieties are zafirlukast and zileuton).

The chemical name of zileuton is N-hydroxy-N-[1-(2-benzothiophene)ethyl]urea, which was developed by Abbott Company in the United States and was approved by the FDA in 1997 to be marketed in the United States for prevention and treatment Chronic asthma over 12 years of age.